THERAPEUTIC AND PHARMACOLOGICAL MONITORING OF TACROLIMUS IN RENAL TRANSPLANT PATIENTS IN C.H.U TIZI OUZOU, ALGERIA.

Simple item page
dc.contributor.authorKACI, Lylia
dc.contributor.authorBADAOUI, L
dc.contributor.authorKENDEL, A
dc.contributor.authorNEKKAR, T
dc.contributor.authorBOUDJELLIL, C
dc.contributor.authorDAHMANI, D
dc.contributor.authorMEKACHER., L.R
dc.date.accessioned2020-09-06T10:05:24Z
dc.date.available2020-09-06T10:05:24Z
dc.date.issued2019
dc.description.abstractImmunosuppressants are now an essential treatment in the prevention of transplant rejection. Tacrolimus a calcineurin inhibitor, works by blocking the production of interleukin 2 by T cells and is currently the cornerstone of immunosuppressive treatment, but its side effects are many and varied (hypertension, diabetes , nephrotoxicity,...). The nephrotoxicity of tacrolimus is a particularly serious problem. Therapeutic and pharmacological monitoring of tacrolimus is a key element in the therapeutic management of renal transplant patients, allowing individual adaptation of prescribing to maintain drug exposure within a predefined concentration range (therapeutic targets) and thus improve efficacy while limiting toxicity. The determination of residual concentrations, is still widely used as a guide for individualizing tacrolimus dosesen
dc.identifier.urihttps://dspace.ummto.dz/handle/ummto/11454
dc.language.isoenen
dc.titleTHERAPEUTIC AND PHARMACOLOGICAL MONITORING OF TACROLIMUS IN RENAL TRANSPLANT PATIENTS IN C.H.U TIZI OUZOU, ALGERIA.en
dc.typeWorking Paperen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
KACI Lylia 2019.pdf
Size:
868.43 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Faculté de Médecine